SCHEMBL6326747

SCHEMBL6326747

COc1cccc(-c2cccc3c2C(=Cc2[nH]c(C)cc2C)C(=O)N3)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 10/20 0.63
ALK Q9UM73 6/20 0.60
KDR P35968 4/20 0.60
FLT3 P36888 4/20 0.60
PDGFRB P09619 3/20 0.60
CSF1R P07333 2/20 0.60
FGFR1 P11362 2/20 0.60
SRC P12931 2/20 0.60
FLT1 P17948 2/20 0.60
FGFR3 P22607 2/20 0.60
MAPK1 P28482 2/20 0.60
FLT4 P35916 2/20 0.60
ABL1 P00519 2/20 0.60
PDPK1 O15530 2/20 0.60
AURKB Q96GD4 2/20 0.60
MEN1 O00255 1/20 0.60
NPC1 O15118 1/20 0.60
GMNN O75496 1/20 0.60
USP2 O75604 1/20 0.60
LMNA P02545 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326741 1.00 RET (0.63) RETALKKDRFLT3PDGFRB
SCHEMBL6323481 0.91 RET (0.64) RETALKKDRFLT3PDGFRB
SCHEMBL6323484 0.91 RET (0.64) RETALKKDRFLT3PDGFRB
SCHEMBL6319463 0.87 KDR (0.48) RETALKKDRFLT3PDGFRB
SCHEMBL6319461 0.87 KDR (0.48) RETALKKDRFLT3PDGFRB
SCHEMBL6319334 0.87 KDR (0.51) RETALKKDRFLT3PDGFRB
SCHEMBL6319328 0.87 KDR (0.51) RETALKKDRFLT3PDGFRB
SCHEMBL6324269 0.85 RET (0.62) RETALKKDRFLT3PDGFRB
SCHEMBL6765924 0.85 RET (0.62) RETALKKDRFLT3PDGFRB
SCHEMBL6320415 0.85 RET (0.62) RETALKKDRFLT3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 RET 658/4885ALK 1015/4885KDR 819/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 RET 658/4885ALK 1015/4885KDR 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.